SNY Sanofi
- 49.740
- -0.470-0.94%
Sanofi News
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
Telecoms stocks led European equities traded in the US as American depositary receipts slightly higher Tuesday morning, rising 0.15% to 1,420.65 on the S&P Europe Select ADR Index. From continental Eu
Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal With Sanofi and Promising Phase 3 Study
Buy Rating for Sanofi: Strong Growth and Attractive Valuation Amidst Pipeline Optionality and Strategic Leadership
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Exploring Three Dividend Stocks On Euronext Paris
Sanofi India's Net Profit Slides in Q1
Sanofi India's (NSE:SANOFI, BOM:500674) net profit declined to 1.37 billion Indian rupees in the first quarter from 1.90 billion rupees a year ago, according to an Indian bourse filing on Monday. Earn
Novavax surged nearly 200% in two days! Big deal with Sanofi draws in capital
Novavax's new multi-billion dollar deal with French pharmaceutical company Sanofi (Sanofi) brought a dramatic turning point for the troubled former, and Wall Street cheered.
AC Immune ACIU Takeda Agreement; Novavax NVAX Sanofi Deal
Novavax's Q1 Results Are Overshadowed by Its Sanofi Partnership
AstraZeneca, Pfizer to Invest Combined $900M+ in France for R&D, Production
Novavax Stock Jumps 50% as Sanofi Deal Kicks off Turning Point for Struggling Vaccine Maker
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker. Novavax said the licensing agreement allows the company to remove its "going concern" warning, which it first issued last year due to substantial doubts about its ability to stay afloat. Some analysts said the deal will provide significant capital to Novavax and "validates" the company's protein-based vaccine platform.
Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts
Barrow, Hanley, Mewhinney & Strauss Bolsters Portfolio With Strategic Additions in Q1 2024
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe
The major US indexes were higher at midday Monday as investors ready themselves for a consequential inflation data release on Wednesday. In company news, shares of GameStop (GME) soared in premarket a
Meme Mania Is Back: Buy These 3 Stocks
The 2020 U.S. equity crash and subsequent rebound was the perfect storm for a unique event called the “Meme” stock craze.
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Healthcare giants Pfizer Inc (NASDAQ:PFE) and AstraZeneca Plc (NASDAQ:AZN) have investments in France, collectively totaling around $1 billion, bolstering the country's healthcare sector. Pfizer revea
Sanofi Gains License for Ex-U.S. Rights to Fulcrum Muscular Dystrophy Candidate
Sartorius Partners With Sanofi for Biomanufacturing Platform
Sartorius (SRT.F, SRT3.F) said Monday it is collaborating with Sanofi (SAN.PA) for the development and marketing of an end-to-end platform for integrated and continuous biomanufacturing, or ICB. Under
Novavax Shares Are Trading Higher on Continued Strength. The Company Last Week Announced a Co-exclusive Licensing Agreement With Sanofi to Commercialize a COVID-19 Vaccine and Develop COVID-influenza Combination Vaccines.
Novavax Shares Are Trading Higher on Continued Strength. The Company Last Week Announced a Co-exclusive Licensing Agreement With Sanofi to Commercialize a COVID-19 Vaccine and Develop COVID-influenza
Analysis
Price Target
No Data
